OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs

IPO Details: OS Therapies has refiled for an initial public offering (IPO) of $6.4 million.
Listing Exchange: The IPO will list on the NYSE American exchange.
Funding Purpose: The funds will be used to support the development of a phase 2 HER2 drug and preclinical antibody-drug conjugates (ADCs).
Immunotherapy Plans: The IPO is part of OS Therapies' broader immunotherapy and ADC development plans.
Recent Activity: The refiling was announced on August 1, 2024.